2nd ALS Drug Development Summit
Evvnt Promotion / evvnt
Archivo
16.05.2023 - 18.05.2023 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
9:00 am - 4:30 pm
Temas de la conferencia
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832
Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832
Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
Información e inscripción:
https://go.evvnt.com/1485150-2?pid=4832
Ms. Erin Thomas
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
